STP2104

STP2104 is an investigational mRNA-based cancer immunotherapy developed by ST Pharm that encodes a modified, ligand-independent analog of the Stimulator of Interferon Genes (STING) protein. Traditional STING agonists often face clinical limitations due to the epigenetic silencing of the STING gene in many tumors, which prevents ligand-dependent activation. STP2104 bypasses this requirement by delivering mRNA that translates into a constitutively active STING protein, thereby triggering robust type I interferon (IFN-β) signaling and NF-κB pathway activation regardless of endogenous STING expression levels. This mechanism promotes the recruitment and activation of cytotoxic T-cells and the conversion of immune-cold tumors into immune-hot environments. Preclinical data indicates that STP2104 exerts a dual anti-tumor effect by both stimulating the innate and adaptive immune systems and directly inhibiting cancer cell proliferation. The therapy is designed for systemic administration via intravenous or intramuscular routes and utilizes a specialized delivery platform (SmartLNP) engineered to reduce hepatic accumulation and associated toxicity.

Other names

STING mRNA therapyligand-independent STING mRNA